PD-L1 in uveal melanoma
1 EU-approved indication in uveal melanoma needs a PD-L1 result: relatlimab + nivolumab (1st line, advanced).
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| PD-L11 | ||||
Opdualag | TPS < 1% | Monotherapy | 1L advanced | Melanoma label; uveal melanoma was excluded from the trials; Aged 12 years and older |
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Relatlimab + nivolumab (Opdualag)
Opdualag is indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%.